ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2026
[Rehmanniae radix preparata alleviates chronic kidney disease in mice through a multi-target mechanism].
Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo explore the mechanisms of Rehmanniae radix preparate (RRP) for alleviating chronic kidney disease (CKD).
methodsThe active components and targets of RRP were identified using TCMSP and BATMAN-TCM databases. A component-target-pathway network was constructed, followed by GO and KEGG enrichment analyses. Molecular docking was performed between the core targets (JUN and STAT3) and the active compounds using AutoDock Vina. For validation of the results, C57BL/6 mice were randomly divided into sham-operated group, unilateral renal ischemia-reperfusion injury (UIRI) model group, and UIRI+RRP treatment group (
resultsA total of 25 active compounds and 307 CKD-related targets were identified, and protein-protein interaction analysis identified 19 hub genes with JUN and STAT3 as the key targets. Molecular docking showed strong binding affinities between the active compounds and JUN/STAT3. The mouse models of UIRI showed significant elevation of serum creatinine, uric acid, blood urea nitrogen, and urinary protein levels with marked tubular injury, interstitial fibrosis, and increased renal expressions of JUN, STAT3, collagen I, and collagen III. RRP treatment significantly reduced these biochemical parameters in the mouse models, improved renal histology, and downregulated JUN, STAT3, and fibrosis-related proteins.
conclusionsThe ameliorative effect of RRP against renal fibrosis and CKD progression in mice is mediated by a multi-component, multi-target, and multi-pathway mechanism targeting the JUN/STAT3 signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.